Education
About Us
Working with TipRanks
Follow Us
CanBas Co., Ltd. (JP:4575)
:4575
4575 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥432.00 - ¥1,512.00
Previous CloseN/A
Volume347.00K
Average Volume (3M)493.82K
Market Cap
¥18.43B
Enterprise Value¥16.81B
Total Cash (Recent Filing)¥2.86B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-18.50
Shares Outstanding19,713,655
10 Day Avg. Volume364,660
30 Day Avg. Volume493,823
Financial Highlights & Ratios
PEG Ratio2.47
Price to Book (P/B)9.54
Price to Sales (P/S)0.00
P/FCF Ratio-13.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
4575 FAQ
What was CanBas Co., Ltd.’s price range in the past 12 months?
CanBas Co., Ltd. lowest stock price was ¥432.00 and its highest was ¥1512.00 in the past 12 months.
What is CanBas Co., Ltd.’s market cap?
CanBas Co., Ltd.’s market cap is ¥18.43B.
When is CanBas Co., Ltd.’s upcoming earnings report date?
CanBas Co., Ltd.’s upcoming earnings report date is Aug 08, 2025 which is in 53 days.
How were CanBas Co., Ltd.’s earnings last quarter?
CanBas Co., Ltd. released its earnings results on May 13, 2025. The company reported -¥18.5 earnings per share for the quarter, missing the consensus estimate of N/A by -¥18.5.
Is CanBas Co., Ltd. overvalued?
According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued.
Does CanBas Co., Ltd. pay dividends?
CanBas Co., Ltd. does not currently pay dividends.
What is CanBas Co., Ltd.’s EPS estimate?
CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanBas Co., Ltd. have?
CanBas Co., Ltd. has 19,713,655 shares outstanding.
What happened to CanBas Co., Ltd.’s price movement after its last earnings report?
CanBas Co., Ltd. reported an EPS of -¥18.5 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.016%.
Which hedge fund is a major shareholder of CanBas Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4575
Company Description
CanBas Co., Ltd.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Technical Analysis
RaQualia Pharma Inc.
―
Kidswell Bio Corporation
―
NanoCarrier Co., Ltd.
―
SanBio Co
―
AnGes
―